Trelegy Ellipta

GSK launches once daily, single inhaler-triple therapy for COPD patients for the first time in India

Bangalore GlaxoSmithKline Pharmaceuticals Limited launched Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol), the first single-inhaler triple therapy (SITT) in India for Chronic Obstructive Pulmonary Disease (COPD) patients in a once-daily regime. The launch follows the product’s approval by the Drugs Controller…

Read More »